Anthony A. Portale, MD

Director, Pediatric Dialysis Program
Pediatric nephrologist

Dr. Anthony A. Portale is a specialist in pediatric kidney disorders. His expertise encompasses genetic diseases of the kidneys and renal tubular system, disorders of bone and mineral metabolism, and acute kidney failure.

Portale's research, which has funding from the National Institutes of Health, focuses on genetic and acquired disorders of calcium, phosphorus and vitamin D metabolism and bone diseases in children. He has contributed more than 80 publications to the medical and scientific literature on these topics.

Portale earned his medical degree at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, part of the State University of New York system. He completed a residency in pediatrics at the John R. Oishei Children's Hospital and a fellowship in pediatric nephrology at UCSF.

Clinics

Kidney Transplant Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 353-8377
Toll-free: (800) 482-7389

Renal Center
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 476-2423

UCSF Pediatric Dialysis Unit
1825 Fourth St., Fifth Floor
San Francisco, CA 94158
Phone: (415) 353-2425
Fax: (415) 353-2768

Conditions & Treatments

More about Anthony A. Portale

Education

Jacobs School of Medicine and Biomedical Sciences, MD 1974

Residencies

John R. Oishei Children's Hospital, Pediatrics 1977

Fellowships

UCSF, Pediatric Nephrology 1981

Selected Research and Publications

  1. Altemose KE, Kumar J, Portale AA, Warady BA, Furth SL, Fadrowski JJ, Atkinson MA. Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease. Pediatr Nephrol. 2018 Jul 14.
  2. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 Jun 26.
  3. Sgambat K, Roem J, Mitsnefes M, Portale AA, Furth S, Warady B, Moudgil A. Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease. Pediatr Nephrol. 2018 Jun 05.
  4. Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, Padidela R, Van't Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018 05 24; 378(21):1987-1998.
  5. Ng DK, Portale AA, Furth SL, Warady BA, Muñoz A. Time-varying coefficient of determination to quantify the explanatory power of biomarkers on longitudinal GFR among children with chronic kidney disease. Ann Epidemiol. 2018 May 17.
  6. Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets. Nat Rev Dis Primers. 2017 Dec 21; 3:17101.
  7. Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, Warady BA, Furth SL, Portale AA. FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clin J Am Soc Nephrol. 2018 Jan 06; 13(1):45-52.
  8. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol. 2016 Nov 07; 11(11):1989-1998.
  9. Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep. 2016 Dec; 5:158-162.
  10. Portale AA, Zhang MY, David V, Martin A, Jiao Y, Gu W, Perwad F. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule. PLoS One. 2015; 10(11):e0142924.
  11. Kumar J, McDermott K, Abraham AG, Friedman LA, Johnson VL, Kaskel FJ, Furth SL, Warady BA, Portale AA, Melamed ML. Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort. Pediatr Nephrol. 2016 Jan; 31(1):121-9.
  12. Zhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Carpenter TO, Peacock M. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol. 2016 Feb; 56(2):176-85.
  13. Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016 Feb; 27(2):543-50.
  14. Ku E, Glidden DV, Hsu CY, Portale AA, Grimes B, Johansen KL. Association of Body Mass Index with Patient-Centered Outcomes in Children with ESRD. J Am Soc Nephrol. 2016 Feb; 27(2):551-8.
  15. Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab. 2015 Jul; 100(7):2565-73.
  16. Ku E, Johansen KL, Portale AA, Grimes B, Hsu CY. State level variations in nephrology workforce and timing and incidence of dialysis in the United States among children and adults: a retrospective cohort study. BMC Nephrol. 2015 Jan 15; 16:2.
  17. Wassner SJ, Chesney RW, Friedman A, Chantler C, Portale AA. Malcolm A. Holliday, M.D, January 12, 1924 - March 26, 2014. Pediatr Nephrol. 2014 Aug; 29(8):1473-4.
  18. Akber A, Portale AA, Johansen KL. Use of pedometers to increase physical activity among children and adolescents with chronic kidney disease. Pediatr Nephrol. 2014 Aug; 29(8):1395-402.
  19. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014 Feb; 9(2):344-53.
  20. Chanakul A, Zhang MY, Louw A, Armbrecht HJ, Miller WL, Portale AA, Perwad F. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS One. 2013; 8(9):e72816.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.